GBA1 Gene Therapy for Parkinson Disease

Edit / manage →

Parkinson disease

PreclinicalDormantGene therapy (AAV)NeurodegenerationConcerning· low conf2 evidence-linked claims

Overview

Disease area: Neurodegeneration
Indication: Parkinson diseaseMONDO:0005180
Mechanism of action: Glucocerebrosidase restoration to reduce alpha-synuclein burden
Development stage: Preclinical
Institution: Lakeshore Neuroscience Institute
Principal investigators: D. Whitfield
Targets: GBA1
Pathways: Lysosomal function
Trial registry: —

Intake & funding

Applications

D. WhitfielddeclinedUSD600,0002024-11-05
Exploratory grant

Funding events

None recorded.

Scientific assessment

1 claims

DifferentiationModerate
GBA1 variants are the most common genetic Parkinson risk factor; restoring glucocerebrosidase may reduce alpha-synuclein burden in a defined subpopulation.
datasetMONDO:0005180

Translational assessment

0 claims

No evidence linked yet.

Regulatory assessment

0 claims

No evidence linked yet.

Commercial assessment

1 claims

Market SizeLimited
GBA-Parkinson is a large genetically defined subset, but companion-diagnostic gating shapes the addressable market.
internalmarket-2024

Execution assessment

0 claims

No evidence linked yet.

Structured reviews

1 reviews

Concerning· low confIndustryNeurodegeneration advisor2025-04-09

Strengths

Large genetically defined subpopulation.

Weaknesses

Indirect mechanism; companion-diagnostic gating; long readouts.

Improvement areas

Strengthen translational link between GCase and clinical benefit.

Internal rubric input (reviewer scoring — not a success probability)

Scientific validity

Translational readiness

Regulatory pathway

Commercial potential

Execution strength

Outcome

Dormant
Paused pending stronger translational link between GCase and clinical benefit.2025-04-09

AI brief

flag off · defaultPhase 7

Runtime AI features are flag-gated and disabled by default. Set SIGNAL_LLM_ENABLED=1 (plus a provider key) to enable a grounded, source-cited brief generated from this asset's structured records — with forbidden-phrase and grounding validators enforcing no probability-of-success or buy/sell language.

Evidence tiers and reviewer rubric scores are internal, qualitative inputs — [signal.] surfaces never show a numeric probability of success or buy/sell language.